T
7.97
0.14 (1.79%)
| 前收盘价格 | 7.83 |
| 收盘价格 | 7.83 |
| 成交量 | 2,057,323 |
| 平均成交量 (3个月) | 2,715,815 |
| 市值 | 1,054,300,160 |
| 价格/销量 (P/S) | 18.14 |
| 股市价格/股市净资产 (P/B) | 9.18 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2025 |
| 营业利益率 (TTM) | -788.76% |
| 稀释每股收益 (EPS TTM) | -1.20 |
| 季度收入增长率 (YOY) | -16.70% |
| 总债务/股东权益 (D/E MRQ) | 22.16% |
| 流动比率 (MRQ) | 6.26 |
| 营业现金流 (OCF TTM) | -135.34 M |
| 杠杆自由现金流 (LFCF TTM) | -67.25 M |
| 资产报酬率 (ROA TTM) | -26.79% |
| 股东权益报酬率 (ROE TTM) | -61.35% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Tango Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.6
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.63 |
|
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 12.59% |
| 机构持股比例 | 97.41% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 15.00 (Stifel, 88.21%) | 购买 |
| 中 | 14.00 (75.66%) | |
| 低 | 12.00 (Guggenheim, 50.57%) | 购买 |
| 平均值 | 13.67 (71.52%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 8.47 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Stifel | 04 Dec 2025 | 15.00 (88.21%) | 购买 | 9.90 |
| B. Riley Securities | 18 Nov 2025 | 14.00 (75.66%) | 购买 | 8.00 |
| Guggenheim | 24 Oct 2025 | 12.00 (50.56%) | 购买 | 7.50 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合